Delos Wealth Advisors’s Anavex Life Sciences AVXL Stock Holding History

Delos Wealth Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,000	Closed	-$9.31K	–	358
2023 Q4	$9.31K	Hold	1,000	–	–	0.01%	101
2023 Q3	$7.9K	Hold	1,000	–	–	0.01%	146
2023 Q2	$8.13K	Hold	1,000	–	–	0.01%	145
2023 Q1	$8.57K	Hold	1,000	–	–	0.01%	136
2022 Q4	$9.26K	Hold	1,000	–	–	0.01%	139
2022 Q3	$10K	Hold	1,000	–	–	0.01%	134
2022 Q2	$10K	Hold	1,000	–	–	0.01%	138
2022 Q1	$12K	Hold	1,000	–	–	0.01%	153
2021 Q4	$17K	Hold	1,000	–	–	0.02%	140
2021 Q3	$18K	Hold	1,000	–	–	0.02%	73
2021 Q2	$23K	Buy	+1,000	New	+$14.8K	0.03%	65

Other funds holding AVXL

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Delos Wealth Advisors's AVXL Position: Q1 2024 in Review

Delos Wealth Advisors sold out of Anavex Life Sciences (AVXL) in Q1 2024, closing a stake of 1,000 shares — an estimated $9.31K sold.

Delos Wealth Advisors first reported a position in AVXL in Q2 2021 and held it in 11 quarters. The position peaked at $23K in Q2 2021. 147 funds tracked by Wall St. Rank hold AVXL as of Q1 2024.

Delos Wealth Advisors reported no remaining Anavex Life Sciences position as of Q1 2024 after selling out during the quarter.
Delos Wealth Advisors sold 1,000 Anavex Life Sciences shares in Q1 2024, an estimated $9.31K.
Delos Wealth Advisors first reported a position in Anavex Life Sciences in Q2 2021 and held it in 11 quarters.
Delos Wealth Advisors's Anavex Life Sciences position peaked at $23K in Q2 2021.
147 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2024.

Based on Delos Wealth Advisors's 13F filing for Q1 2024, filed 9 May 2024.